Ongoing endeavors are made to identify additional genomic or immune-mediated biomarkers that can forecast response to specific treatments, beyond tumor histology, starting with the site-agnostic indication of pembrolizumab for patients with MSI-unstable tumors and the inhibition of TRK in NTRK fusion-positive cancers [19]. This evidence concerns the gene NTRK1 and neoplasm.